Kamlesh Sajnani, MD
Medical Oncology · Harlan, KYNPI 1730490152
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,861 of the $2,465 with a category attached, or 75.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in KY, where the typical reported total is $3,396.
Across 103 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Athenex Pharmaceutical Division, LLC$350
- Novocure GmbH$250
- Novartis$176
- Pfizer$171
- AstraZeneca$163
- GSK$161
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$60024%
- Food & beverage$1,86176%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Novocure GmbH | 1 | $250 |
| Novartis | 10 | $176 |
| Pfizer | 9 | $171 |
| AstraZeneca | 7 | $163 |
| GSK | 6 | $161 |
| Daiichi Sankyo Inc. | 7 | $120 |
| Johnson & Johnson | 6 | $112 |
| Bristol Myers Squibb | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Lilly USA, LLC | 6 | $90 |
| Array Biopharma Inc | 6 | $77 |
| Gilead(2 entities) | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Rigel Pharmaceuticals, Inc. | 2 | $49 |
| Astellas Pharma US Inc | 3 | $48 |
| Amgen | 3 | $47 |
| AbbVie | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Bayer | 1 | $25 |
| Tempus AI, Inc | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
How this compares
$2,465 in reported general payments places this provider in the 45th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImfinziDurvalumab | 17 | $265,511 |
| ImbruvicaIbrutinib | 15 | $242,788 |
| PomalystPomalidomide | 12 | $235,302 |
| KeytrudaPembrolizumab | 14 | $156,950 |
| XtandiEnzalutamide | 13 | $93,294 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $60,500 |
| DarzalexDaratumumab | 16 | $51,726 |
| Abiraterone Acetate | 25 | $31,164 |
| NivestymFilgrastim-Aafi | 12 | $20,690 |
| Anastrozole | 132 | $1,338 |
| Ondansetron OdtOndansetron | 76 | $1,247 |
| Acyclovir | 12 | $609 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $559 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $547 |
| Oxycodone Hcl | 23 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaImfinzi | $163 | $265,51117 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $92 | $235,30212 claims |
| MerckKeytruda | $17 | $156,95014 claims |
| Astellas Pharma US IncXtandi | $48 | $93,29413 claims |
| Johnson & JohnsonDarzalex | $112 | $51,72616 claims |
| PfizerNivestym | $171 | $20,69012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Harlan
- Minsig ChoiEdgewood$348K
- Lowell AnthonyLexington$55K
- Matthew KurianEdgewood$47K
- Jewraj MaheshwariOwensboro$36K
- Emmanuel NidhiryLouisville$34K
- John HammLouisville$26K
- Wederson ClaudinoPaducah$25K
- Renato la RoccaLouisville$24K
- Kent TaylorGeorgetown$22K
- Douglas FloraEdgewood$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.